Halozyme Therapeutics — Third Quarter 2026 Earnings Summary

Halozyme Therapeutics reported third-quarter 2026 total revenue of $493 million, a 39% year-over-year increase driven by a 44% rise in royalty revenue to $341 million. The company raised its full-year 2026 financial guidance, projecting total revenue between $1.860 billion and $1.925 billion and non-GAAP diluted earnings per share between $8.75 and $9.05. Strategic milestones included expanding collaboration agreements with partners such as argenx, Incyte, and Johnson & Johnson, while three ENHANZE programs advanced into Phase 1 clinical development. Additionally, a Dutch patent court granted an injunction against Merck for infringing Halozyme's MDASE patents, prohibiting the sale of Keytruda Qlex in multiple European markets.